Equillium, Inc. (FRA:0FY)

Market Cap	72.78M +201.9%
Revenue (ttm)	3.74M -90.4%
Net Income	-20.81M
EPS	-0.49
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	842
Open	0.9320
Previous Close	0.8640
Day's Range	0.9260 - 0.9340
52-Week Range	0.2500 - 1.7600
Beta	n/a
RSI	52.69
Earnings Date	Mar 23, 2026

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 35
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0FY

Financial Performance

In 2024, Equillium's revenue was $41.10 million, an increase of 13.89% compared to the previous year's $36.08 million. Losses were -$8.07 million, -39.51% less than in 2023.

Financial numbers in USD